Effective Treatment of Severe COVID-19 Patients with Tocilizumab
摘要: Background: In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China, which spread rapidly and has become a world-wide public health challenge. We aimed to assess the efficacy of tocilizumab in severe patients with Corona Virus Disease-19 (COVID-19) and seek a new therapeutic strategy. Methods: The patients diagnosed as severe or critical COVID-19 in The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) and Anhui Fuyang Second People’s Hospital were given tocilizumab in addition to routine therapy between February 5 and February 14, 2020. The changes of clinical manifestations, CT scan image, and laboratory examinations were retrospectively analyzed. Findings: Within a few days, the fever returned to normal and all other symptoms improved remarkably. Fifteen of the 20 patients (75.0%) had lowered their oxygen intake and one patient need no oxygen therapy. CT scans manifested that the lung lesion opacity absorbed in 19 patients (90.5%). The percentage of lymphocytes in peripheral blood, which decreased in 85.0% patients (17/20) before treatment (mean, 15.52 ± 8.89%), returned to normal in 52.6% patients (10/19) on the fifth day after treatment. Abnormally elevated C-reactive protein decreased significantly in 84.2% patients (16/19). No obvious adverse reactions were observed. Nineteen patients (90.5%) have been discharged on average 13.5 days after the treatment with tocilizumab and the rest are recovering well. Interpretation: Tocilizumab is an effective treatment in severe patients of COVID-19, which provided a new therapeutic strategy for this fatal infectious disease.
[V1] | 2020-03-05 16:04:07 | ChinaXiv:202003.00026V1 | 下载全文 |
1. Premalignant gastric lesions,Immunotherapy and Chinese medicine 2023-01-20 |
2. 非酒精性脂肪性肝病临床指南和共识的质量评价及推荐意见比较研究 2023-01-09 |
3. 非小细胞肺癌患者PD-L1抑制剂和Nab紫杉醇的剂量方案优化:定量系统药理学分析 2022-12-26 |
4. 膳食炎症指数与上消化道肿瘤风险关系的Meta分析 2022-12-23 |
5. SOFA评分、CURB-65评分及PSI评分对重症肺炎患者28天病死率的预测价值 2022-12-23 |
6. 家庭肠内营养在食管癌患者中有效性和安全性的meta分析 2022-12-23 |
7. Remedial dosing recommendations for valproic acid in nonadherence patients with epilepsy 2022-12-22 |
8. 人工智能应用于糖尿病视网膜病变的可视化分析 2022-12-20 |
9. 基于Web of Science数据库的未分化疾病文献计量学和可视化分析 2022-12-20 |
10. 抑郁症患者药物治疗偏好的系统综述——基于离散选择实验和优劣尺度法 2022-12-01 |